BioAtla, Inc. (BCAB)
1.26
-0.06
(-4.55%)
USD |
OTCM |
Sep 08, 16:00
BioAtla Enterprise Value : 6.415M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 6.415M |
| September 04, 2026 | 6.515M |
| September 03, 2026 | 6.481M |
| September 02, 2026 | 6.323M |
| September 01, 2026 | 6.115M |
| August 31, 2026 | 7.13M |
| August 28, 2026 | 7.205M |
| August 27, 2026 | 9.542M |
| August 26, 2026 | 9.508M |
| August 25, 2026 | 9.741M |
| August 24, 2026 | 9.775M |
| August 21, 2026 | 9.608M |
| August 20, 2026 | 9.608M |
| August 19, 2026 | 9.758M |
| August 18, 2026 | 9.608M |
| August 17, 2026 | 9.409M |
| August 14, 2026 | 9.459M |
| August 13, 2026 | 10.06M |
| August 12, 2026 | 9.941M |
| August 11, 2026 | 10.14M |
| August 10, 2026 | 10.09M |
| August 07, 2026 | 10.07M |
| August 06, 2026 | 9.858M |
| August 05, 2026 | 9.850M |
| August 04, 2026 | 9.891M |
| Date | Value |
|---|---|
| August 03, 2026 | 9.741M |
| July 31, 2026 | 9.791M |
| July 30, 2026 | 9.941M |
| July 29, 2026 | 9.675M |
| July 28, 2026 | 10.19M |
| July 27, 2026 | 9.974M |
| July 24, 2026 | 9.924M |
| July 23, 2026 | 10.07M |
| July 22, 2026 | 9.958M |
| July 21, 2026 | 10.46M |
| July 20, 2026 | 10.47M |
| July 17, 2026 | 10.89M |
| July 16, 2026 | 10.96M |
| July 15, 2026 | 11.40M |
| July 14, 2026 | 11.07M |
| July 13, 2026 | 10.82M |
| July 10, 2026 | 10.67M |
| July 09, 2026 | 10.51M |
| July 08, 2026 | 10.29M |
| July 07, 2026 | 11.11M |
| July 06, 2026 | 11.94M |
| July 02, 2026 | 11.29M |
| July 01, 2026 | 11.11M |
| June 30, 2026 | 11.21M |
| June 29, 2026 | 321.95M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.79B |
| Oncolytics Biotech, Inc. | 96.67M |
| Sangamo Therapeutics, Inc. | 58.40M |
| Sarepta Therapeutics, Inc. | 2.469B |
| Anixa Biosciences, Inc. | 83.62M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.452M |
| Revenue (Quarterly) | 6.50M |
| Total Expenses (Quarterly) | 6.048M |
| EPS Diluted (Quarterly) | 0.272 |
| Profit Margin (Quarterly) | 6.95% |
| Earnings Yield | -19.42% |
| Normalized Earnings Yield | -26.98 |